ATE255882T1 - Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren - Google Patents

Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren

Info

Publication number
ATE255882T1
ATE255882T1 AT98930447T AT98930447T ATE255882T1 AT E255882 T1 ATE255882 T1 AT E255882T1 AT 98930447 T AT98930447 T AT 98930447T AT 98930447 T AT98930447 T AT 98930447T AT E255882 T1 ATE255882 T1 AT E255882T1
Authority
AT
Austria
Prior art keywords
liposomes
polynucleotide composition
polynucleotide
liposome
composition
Prior art date
Application number
AT98930447T
Other languages
German (de)
English (en)
Inventor
Theresa M Allen
Darrin Stuart
Original Assignee
Sequus Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequus Pharm Inc filed Critical Sequus Pharm Inc
Application granted granted Critical
Publication of ATE255882T1 publication Critical patent/ATE255882T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98930447T 1997-06-23 1998-06-22 Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren ATE255882T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5049097P 1997-06-23 1997-06-23
PCT/US1998/012937 WO1998058630A1 (en) 1997-06-23 1998-06-22 Liposome-entrapped polynucleotide composition and method

Publications (1)

Publication Number Publication Date
ATE255882T1 true ATE255882T1 (de) 2003-12-15

Family

ID=21965541

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930447T ATE255882T1 (de) 1997-06-23 1998-06-22 Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren

Country Status (11)

Country Link
US (1) US6120798A (OSRAM)
EP (1) EP1017365B1 (OSRAM)
JP (1) JP2002508765A (OSRAM)
AT (1) ATE255882T1 (OSRAM)
AU (1) AU7983798A (OSRAM)
CA (1) CA2294579C (OSRAM)
DE (1) DE69820465T2 (OSRAM)
DK (1) DK1017365T3 (OSRAM)
ES (1) ES2212305T3 (OSRAM)
TW (1) TWI225412B (OSRAM)
WO (1) WO1998058630A1 (OSRAM)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
EP1150658B1 (en) * 1999-02-08 2004-08-04 Alza Corporation Method for controlling liposome size
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US20020146829A1 (en) * 2000-11-29 2002-10-10 Aventis Pharmaceuticals Products Inc. Neutral and anionic colloidal particles for gene delivery
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
EP1460898A4 (en) * 2002-01-03 2006-05-24 Univ Texas WT1 ANTISENSE OLIGOS FOR THE INHIBITION OF BREAST CANCER
KR100466254B1 (ko) * 2002-02-25 2005-01-14 한국과학기술원 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법
EP1509203B1 (en) * 2002-05-15 2016-04-13 California Pacific Medical Center Delivery of nucleic acid-like compounds
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
JP4975964B2 (ja) 2002-06-26 2012-07-11 メディゲーネ アクチエンゲゼルシャフト 脂肪親和性化合物から成る陽イオン性リポソームの製法
EP1519714B1 (en) * 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
AU2002953285A0 (en) * 2002-12-12 2003-01-02 Protech Research Pty Ltd Yeast treatment
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
ES2366617T3 (es) 2003-04-21 2011-10-21 Epeius Biotechnologies Corporation Métodos y composiciones para el tratamiento de transtornos.
CA2566079A1 (en) * 2004-05-12 2005-12-01 Terrence L. Scott Nucleic acid microspheres, production and delivery thereof
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
WO2007080902A1 (ja) 2006-01-11 2007-07-19 Kyowa Hakko Kogyo Co., Ltd. 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤
US20110091377A1 (en) 2007-05-11 2011-04-21 The Johns Hopkins University Biomarkers for melanoma
PL208054B1 (pl) * 2007-09-06 2011-03-31 Akademia Medyczna Im Piastow Śląskich We Wrocławiu Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie
CA2710983A1 (en) * 2007-12-27 2009-10-01 The Ohio State University Research Foundation Lipid nanoparticle compositions and methods of making and using the same
WO2009137095A2 (en) 2008-05-08 2009-11-12 The Johns Hopkins University Compositions and methods for modulating an immune response
WO2010013815A1 (ja) 2008-08-01 2010-02-04 協和発酵キリン株式会社 標的遺伝子の発現を抑制する組成物
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2755773A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
MX2011010072A (es) 2009-03-27 2011-10-06 Merck Sharp & Dohme Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2474306B1 (en) 2009-08-31 2016-11-09 NanoCarrier Co., Ltd. Particle composition and medicinal composition comprising same
JP4653242B1 (ja) 2010-02-12 2011-03-16 ナノキャリア株式会社 粒子状医薬組成物
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
JP5902617B2 (ja) 2010-04-28 2016-04-13 協和発酵キリン株式会社 カチオン性脂質
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
JP5913292B2 (ja) 2010-05-14 2016-04-27 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 代謝を調節する組成物および方法
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
US9233997B2 (en) 2010-08-26 2016-01-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
JP5952197B2 (ja) 2011-01-19 2016-07-13 協和発酵キリン株式会社 標的遺伝子の発現を抑制する組成物
JP2013095755A (ja) 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
EP2780455B1 (en) 2011-11-17 2017-07-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Auto-recognizing therapeutic rna/dna chimeric nanoparticles (np)
US20150240238A1 (en) 2011-11-17 2015-08-27 The Regents Of The University Of California Therapeutic rna switches compositions and methods of use
AU2012353463B2 (en) 2011-12-12 2017-08-24 Kyowa Hakko Kirin Co., Ltd. Lipid nanoparticles containing combinations of cationic lipids
JP6182457B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
CA2860731C (en) 2012-01-10 2023-02-28 M. Mahmood Hussain Method of treating hyperlipidemia and atherosclerosis with mir-30c
EP3865123A1 (en) 2012-03-29 2021-08-18 Translate Bio, Inc. Lipid-derived neutral nanoparticles
AU2013266238B2 (en) 2012-05-23 2017-07-27 The Ohio State University Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same
US10502737B2 (en) 2012-05-25 2019-12-10 The University Of Vermont And State Agriculture College Anti-thrombotic compositions and methods for assaying platelet reactivity and treatment selection
TW201726599A (zh) 2012-07-06 2017-08-01 協和醱酵麒麟有限公司 陽離子性脂質
US9913907B2 (en) 2012-07-16 2018-03-13 Kyowa Hakko Kirin Co., Ltd. RNAi pharmaceutical composition for suppressing expression of KRAS gene
JP6000033B2 (ja) * 2012-09-18 2016-09-28 株式会社ピカソ美化学研究所 内包物質に耐熱性を与えたリポソーム及びその製造方法
EP2967078B1 (en) 2013-03-14 2018-10-17 GenVivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
EP3158992A1 (en) * 2015-10-21 2017-04-26 Universität Heidelberg Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
EP3373939A4 (en) 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University MEDIUM AND METHOD FOR REDUCING TUMORIGENITY OF CANCER STEM CELLS
US11998540B2 (en) 2015-12-11 2024-06-04 The General Hospital Corporation Compositions and methods for treating drug-tolerant glioblastoma
TW201726614A (zh) 2015-12-25 2017-08-01 Kyowa Hakko Kirin Co Ltd 作為陽離子性脂質之化合物
CN116536272A (zh) 2018-04-06 2023-08-04 儿童医疗中心有限公司 用于体细胞重新编程和调整印记的组合物和方法
EP3628309A1 (en) 2018-09-28 2020-04-01 Universität Heidelberg Method of making oral dosage forms
IL294441A (en) * 2019-12-31 2022-09-01 Fred Hutchinson Cancer Center Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites
EP4161552A1 (en) 2020-06-05 2023-04-12 The Broad Institute, Inc. Compositions and methods for treating neoplasia
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
AU2022368907A1 (en) 2021-10-20 2024-05-02 University Of Copenhagen Rejuvenation treatment of age-related white matter loss
EP4658294A2 (en) 2023-02-02 2025-12-10 University of Rochester Competitive replacement of glial cells
WO2024226499A1 (en) 2023-04-24 2024-10-31 The Broad Institute, Inc. Compositions and methods for modifying fertility
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
CA2222328C (en) * 1995-06-07 2012-01-10 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU6691496A (en) * 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
FR2751222B1 (fr) * 1996-07-16 1998-10-09 Capsulis Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique

Also Published As

Publication number Publication date
CA2294579A1 (en) 1998-12-30
AU7983798A (en) 1999-01-04
JP2002508765A (ja) 2002-03-19
HK1025906A1 (en) 2000-12-01
DK1017365T3 (da) 2004-03-29
TWI225412B (en) 2004-12-21
CA2294579C (en) 2007-10-09
ES2212305T3 (es) 2004-07-16
EP1017365B1 (en) 2003-12-10
US6120798A (en) 2000-09-19
DE69820465D1 (de) 2004-01-22
DE69820465T2 (de) 2004-09-16
WO1998058630A1 (en) 1998-12-30
EP1017365A1 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
DE69820465D1 (de) Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren
ZA885450B (en) Method of manufacturing unilamellar lipid vesicles
AU569314B2 (en) Method of preparing liposomes and liposomal compositions
DE69614385D1 (de) Verfahren zur herstellung einer liposomen-zubereitung
DE3867637D1 (de) Paucilamellare lipidvesikel.
PT76245B (de) Verfahren zur herstellung von unilamellaren liposomen in waessriger phase
CA2191077A1 (en) Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
DE69529225D1 (de) Verfahren zur herstellung dopppelschichtiger lipidmembranen
ES2152324T3 (es) Vesiculas lipidicas multilaminares bifasicas.
CA2270396A1 (en) Cationic reagents for transfection
DE3482161D1 (de) Zubereitung von arzneimittelhaltigen lipidvesikeln und verfahren zu deren herstellung.
IL115849A0 (en) Tangential filtration preparation of liposomal drugs and liposome product thereof
DE69616523D1 (de) Verfahren zur baladung von lipidvesikeln
CA2148311A1 (en) Lipid Vesicles, Their Process of Production and Their Applications
DK0671904T3 (da) Antibiotisk præparat og anvendelse mod lægemiddelresistente infektioner
ATE223205T1 (de) Verfahren zur herstellung von liposomen, die hydrophobische artzneistoffe enthalten
EP1042423A4 (en) PROCESS FOR FORMING ANTI-CORROSION LAYERS WITH HYDROGEN BENZOTRIAZOLE DERIVATIVES
FI873111L (fi) Menetelmä yksittäisten kaksikerroksisten liposomien valmistamiseksi
EP0787853A4 (en) THREE-DIMENSIONAL PRINTED FABRIC AND ITS MANUFACTURING METHOD
CA2346016A1 (en) Glucoside paucilamellar vesicles
AU629982B2 (en) Hydrophilic laminated porous membranes and methods of preparing same
AU6524990A (en) Hybrid paucilamellar lipid vesicles
AU6323590A (en) Hydrophilic laminated porous membranes and methods of preparing same
DE69018258D1 (de) Aktive Bestandteile enthaltende phospholipidische Liposome und Verfahren zu ihrer Herstellung.
WO2003018018A3 (en) Vinorelbine compositions and methods of use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties